JP2022543136A5 - - Google Patents

Info

Publication number
JP2022543136A5
JP2022543136A5 JP2022506919A JP2022506919A JP2022543136A5 JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5 JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
approximately
dose
apoc3
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506919A
Other languages
English (en)
Japanese (ja)
Other versions
JP7829478B2 (ja
JP2022543136A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044879 external-priority patent/WO2021026150A1/en
Publication of JP2022543136A publication Critical patent/JP2022543136A/ja
Publication of JP2022543136A5 publication Critical patent/JP2022543136A5/ja
Priority to JP2025012194A priority Critical patent/JP2025061882A/ja
Application granted granted Critical
Publication of JP7829478B2 publication Critical patent/JP7829478B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506919A 2019-08-05 2020-08-04 Ａｐｏｃ３関連疾患および障害の処置のための方法 Active JP7829478B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025012194A JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962883046P 2019-08-05 2019-08-05
US62/883,046 2019-08-05
US201962936559P 2019-11-17 2019-11-17
US62/936,559 2019-11-17
US202062970613P 2020-02-05 2020-02-05
US62/970,613 2020-02-05
PCT/US2020/044879 WO2021026150A1 (en) 2019-08-05 2020-08-04 Methods for the treatment of apoc3-related diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025012194A Division JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Publications (3)

Publication Number Publication Date
JP2022543136A JP2022543136A (ja) 2022-10-07
JP2022543136A5 true JP2022543136A5 (enExample) 2023-08-14
JP7829478B2 JP7829478B2 (ja) 2026-03-13

Family

ID=74503223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506919A Active JP7829478B2 (ja) 2019-08-05 2020-08-04 Ａｐｏｃ３関連疾患および障害の処置のための方法
JP2025012194A Pending JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025012194A Pending JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Country Status (10)

Country Link
US (1) US20220152079A1 (enExample)
EP (1) EP4010075A4 (enExample)
JP (2) JP7829478B2 (enExample)
KR (1) KR20220044551A (enExample)
CN (1) CN114555188A (enExample)
AU (2) AU2020324974B2 (enExample)
CA (1) CA3147725A1 (enExample)
MX (1) MX2022001460A (enExample)
TW (1) TW202120104A (enExample)
WO (1) WO2021026150A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
CN114934074A (zh) * 2022-06-01 2022-08-23 北京大学 一种ApoC3基因敲除仓鼠模型的构建方法
WO2024245381A1 (zh) 2023-06-01 2024-12-05 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
WO2026049536A1 (en) * 2024-08-30 2026-03-05 Olix Pharmaceuticals, Inc. RNAi AGENT TARGETING APOC3 GENE AND USE THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2505292C2 (ru) * 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
CA2839573A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP2723756B1 (en) * 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
TWI865997B (zh) * 2016-12-16 2024-12-11 美商阿尼拉製藥公司 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
CN111164091B (zh) 2017-06-02 2025-01-07 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
SG11201912178VA (en) * 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
CN118291456A (zh) * 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Similar Documents

Publication Publication Date Title
JP2015520188A5 (enExample)
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
JP2022173519A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
JP2025096283A5 (enExample)
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
JP2023061957A (ja) 抑うつ障害の処置
JP2018531605A5 (enExample)
JP6440843B2 (ja) 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
JP2022518944A5 (enExample)
JP7829478B2 (ja) Ａｐｏｃ３関連疾患および障害の処置のための方法
JP5837877B2 (ja) 静脈内投与イブプロフェンを用いた患者の治療
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
TW202417015A (zh) 以非妥西蘭治療血友病
US20240358668A1 (en) Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
US20230348586A1 (en) Therapeutic agents and uses thereof
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
TW202220650A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物
EP3996679A1 (en) High concentration insulin formulation
JP2003171266A (ja) キシリトールを含有する解熱性調剤
Nuffer et al. The Role of inhaled insulin in the management of Type 2 Diabetes
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法